Home » Industry At-A-Glance » CHI Industry Details
Organization Information
3624 Tolenas Court
Sacramento CA 95864
Phone: (800) 444-5052
www.sanofi-aventis.com
Ownership: Public
Stock Symbol: (ADR) (SNY)
Revenue: $34.2 Billion
Our Leadership
- Jean-François Dehecq, Chairman
- Ed Greissing, Vice President, Government Relations
- Chris Viehbacher, CEO
- Eddie D. Evans, Vice President, Federal Government Affairs
- Danielle Walters, Vice President, State Government Affairs and Commercial Interface
- James Boyd, Head of North America Regional Center
- Richard M. Hodge, Senior Manager, Federal Relations & Public Policy
- Saira Sultan, Director, Federal Affairs
- Ann Taylor, Director, Public Policy
- Deanne Calvert, Sr. Manager, State Government Affairs
- Amy Redl, Manager, Federal Government Relations
- Peter Rubin, Senior Director, Federal Government Affairs
Sanofi-Aventis
Organization Profile
Sanofi-Aventis is an international pharmaceutical group engaged in the research, development, manufacture and marketing of pharmaceutical products for sale principally in the prescription market. Sanofi-Avenits specializes in seven therapeutic areas: cardiovascular, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines. The Company's five strategic products Aprovel, Eloxatin, Plavix, Stilnox and Xatral, together, accounted for 54.7% of total consolidated net sales during the year ended December 31, 2003. In addition, Sanofi-Avenits has 56 compounds in development in the four therapeutic areas, 25 of which were in Phase II or Phase III clinical trials. The Company also manufactures and markets a variety of generics in France, Germany and the United Kingdom. On August 20, 2004, Sanofi-Synthelabo merged with Aventis, and changed its name from Sanofi-Synthelabo to Sanofi-Aventis.